Embecta Corp. (NASDAQ: EMBCV) Stock Competitors & Peer Comparison

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TAK has a market cap of 55.4B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TAK trades at $17.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 12.52. In terms of profitability, EMBCV's ROE is -0.19%, compared to TAK's ROE of +0.02%. Regarding short-term risk, EMBCV is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TAK's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HLN has a market cap of 43.2B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while HLN trades at $9.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 18.28. In terms of profitability, EMBCV's ROE is -0.19%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EMBCV is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check HLN's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TEVA has a market cap of 42.8B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TEVA trades at $37.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is 12.54. In terms of profitability, EMBCV's ROE is -0.19%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, EMBCV is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TEVA's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, VTRS has a market cap of 18.7B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while VTRS trades at $16.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is 6.39. In terms of profitability, EMBCV's ROE is -0.19%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, EMBCV is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check VTRS's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ITCI trades at $131.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EMBCV's ROE is -0.19%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EMBCV is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ITCI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CTLT trades at $63.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EMBCV's ROE is -0.19%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EMBCV is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CTLT's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ELAN has a market cap of 11.1B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ELAN trades at $22.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is 20.91. In terms of profitability, EMBCV's ROE is -0.19%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, EMBCV is more volatile compared to ELAN. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ELAN's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RDY has a market cap of 10.3B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while RDY trades at $12.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 20.30. In terms of profitability, EMBCV's ROE is -0.19%, compared to RDY's ROE of +0.09%. Regarding short-term risk, EMBCV is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check RDY's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while LNTH trades at $100.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 16.93. In terms of profitability, EMBCV's ROE is -0.19%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, EMBCV is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check LNTH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AMRX has a market cap of 5.6B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AMRX trades at $17.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is 19.62. In terms of profitability, EMBCV's ROE is -0.19%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, EMBCV is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AMRX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while INDV trades at $38.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas INDV's P/E ratio is 10.61. In terms of profitability, EMBCV's ROE is -0.19%, compared to INDV's ROE of -2.16%. Regarding short-term risk, EMBCV is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check INDV's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SUPN trades at $47.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is 15.64. In terms of profitability, EMBCV's ROE is -0.19%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, EMBCV is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SUPN's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while RGC trades at $5.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -356.34. In terms of profitability, EMBCV's ROE is -0.19%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EMBCV is more volatile compared to RGC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check RGC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while BHC trades at $6.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas BHC's P/E ratio is 1.58. In terms of profitability, EMBCV's ROE is -0.19%, compared to BHC's ROE of +0.89%. Regarding short-term risk, EMBCV is more volatile compared to BHC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check BHC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while DCPH trades at $25.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EMBCV's ROE is -0.19%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EMBCV is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check DCPH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HCM has a market cap of 2.1B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while HCM trades at $12.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 4.59. In terms of profitability, EMBCV's ROE is -0.19%, compared to HCM's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to HCM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check HCM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AVDL trades at $21.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EMBCV's ROE is -0.19%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, EMBCV is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AVDL's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while DVAX trades at $15.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EMBCV's ROE is -0.19%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, EMBCV is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check DVAX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PRGO trades at $12.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is 5.07. In terms of profitability, EMBCV's ROE is -0.19%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, EMBCV is more volatile compared to PRGO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PRGO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ANIP trades at $75.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is 9.14. In terms of profitability, EMBCV's ROE is -0.19%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, EMBCV is more volatile compared to ANIP. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ANIP's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TARO trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, EMBCV's ROE is -0.19%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EMBCV is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TARO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while HROW trades at $39.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas HROW's P/E ratio is 437.33. In terms of profitability, EMBCV's ROE is -0.19%, compared to HROW's ROE of -1.04%. Regarding short-term risk, EMBCV is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check HROW's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PAHC trades at $34.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 11.54. In terms of profitability, EMBCV's ROE is -0.19%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EMBCV is more volatile compared to PAHC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PAHC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ALVO has a market cap of 1.4B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ALVO trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is -11.79. In terms of profitability, EMBCV's ROE is -0.19%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EMBCV is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ALVO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CRON trades at $3.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CRON's P/E ratio is 30.10. In terms of profitability, EMBCV's ROE is -0.19%, compared to CRON's ROE of +0.06%. Regarding short-term risk, EMBCV is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CRON's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ETON has a market cap of 1.1B. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ETON trades at $42.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ETON's P/E ratio is -594.00. In terms of profitability, EMBCV's ROE is -0.19%, compared to ETON's ROE of -0.06%. Regarding short-term risk, EMBCV is more volatile compared to ETON. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ETON's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PCRX has a market cap of 932.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PCRX trades at $23.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is 9.12. In terms of profitability, EMBCV's ROE is -0.19%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, EMBCV is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PCRX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PETQ trades at $30.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EMBCV's ROE is -0.19%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EMBCV is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PETQ's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AMPH has a market cap of 881M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AMPH trades at $20.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 6.82. In terms of profitability, EMBCV's ROE is -0.19%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EMBCV is more volatile compared to AMPH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AMPH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, COLL has a market cap of 842.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while COLL trades at $28.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 3.26. In terms of profitability, EMBCV's ROE is -0.19%, compared to COLL's ROE of +0.16%. Regarding short-term risk, EMBCV is more volatile compared to COLL. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check COLL's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EVO has a market cap of 778M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while EVO trades at $2.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -3.09. In terms of profitability, EMBCV's ROE is -0.19%, compared to EVO's ROE of -0.24%. Regarding short-term risk, EMBCV is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check EVO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while IRWD trades at $4.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is 5.54. In terms of profitability, EMBCV's ROE is -0.19%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, EMBCV is more volatile compared to IRWD. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check IRWD's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while BDSI trades at $5.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EMBCV's ROE is -0.19%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EMBCV is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check BDSI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EOLS has a market cap of 534.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while EOLS trades at $8.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -25.71. In terms of profitability, EMBCV's ROE is -0.19%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, EMBCV is more volatile compared to EOLS. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check EOLS's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AQST has a market cap of 530.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AQST trades at $4.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -6.93. In terms of profitability, EMBCV's ROE is -0.19%, compared to AQST's ROE of +2.44%. Regarding short-term risk, EMBCV is more volatile compared to AQST. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AQST's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TLRY has a market cap of 523.4M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TLRY trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -4.32. In terms of profitability, EMBCV's ROE is -0.19%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, EMBCV is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TLRY's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CGC has a market cap of 432.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CGC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -0.62. In terms of profitability, EMBCV's ROE is -0.19%, compared to CGC's ROE of -0.33%. Regarding short-term risk, EMBCV is more volatile compared to CGC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CGC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, KMDA has a market cap of 396.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while KMDA trades at $7.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 19.66. In terms of profitability, EMBCV's ROE is -0.19%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EMBCV is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check KMDA's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TKNO has a market cap of 396.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TKNO trades at $7.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -23.84. In terms of profitability, EMBCV's ROE is -0.19%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, EMBCV is more volatile compared to TKNO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TKNO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ALIM trades at $5.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EMBCV's ROE is -0.19%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EMBCV is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ALIM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EMBC has a market cap of 281.8M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while EMBC trades at $5.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas EMBC's P/E ratio is 1.83. In terms of profitability, EMBCV's ROE is -0.19%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, EMBCV is more volatile compared to EMBC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check EMBC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while LNDC trades at $8.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EMBCV's ROE is -0.19%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, EMBCV is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check LNDC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ACB has a market cap of 236.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ACB trades at $3.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ACB's P/E ratio is -7.80. In terms of profitability, EMBCV's ROE is -0.19%, compared to ACB's ROE of -0.21%. Regarding short-term risk, EMBCV is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ACB's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ORGO has a market cap of 232.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ORGO trades at $1.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is 60.33. In terms of profitability, EMBCV's ROE is -0.19%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, EMBCV is more volatile compared to ORGO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ORGO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TYHT trades at $11.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EMBCV's ROE is -0.19%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, EMBCV is more volatile compared to TYHT. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TYHT's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SIGA has a market cap of 205.8M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SIGA trades at $2.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 10.63. In terms of profitability, EMBCV's ROE is -0.19%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, EMBCV is more volatile compared to SIGA. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SIGA's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OGI has a market cap of 181.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while OGI trades at $1.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas OGI's P/E ratio is -4.96. In terms of profitability, EMBCV's ROE is -0.19%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EMBCV is more volatile compared to OGI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check OGI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LFCR has a market cap of 178.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while LFCR trades at $4.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -4.46. In terms of profitability, EMBCV's ROE is -0.19%, compared to LFCR's ROE of -2.51%. Regarding short-term risk, EMBCV is more volatile compared to LFCR. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check LFCR's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while REPH trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, EMBCV's ROE is -0.19%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EMBCV is more volatile compared to REPH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check REPH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while DERM trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -17.38. In terms of profitability, EMBCV's ROE is -0.19%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EMBCV is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check DERM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CRDL has a market cap of 175.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CRDL trades at $1.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -5.41. In terms of profitability, EMBCV's ROE is -0.19%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EMBCV is more volatile compared to CRDL. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CRDL's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while THTX trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -28.83. In terms of profitability, EMBCV's ROE is -0.19%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EMBCV is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check THTX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ASRT trades at $23.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EMBCV's ROE is -0.19%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EMBCV is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ASRT's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CPIX has a market cap of 119.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CPIX trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -19.90. In terms of profitability, EMBCV's ROE is -0.19%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, EMBCV is more volatile compared to CPIX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CPIX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SCTL trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EMBCV's ROE is -0.19%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EMBCV is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SCTL's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BGM has a market cap of 111.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while BGM trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -1.01. In terms of profitability, EMBCV's ROE is -0.19%, compared to BGM's ROE of -0.07%. Regarding short-term risk, EMBCV is more volatile compared to BGM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check BGM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PROC trades at $1.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, EMBCV's ROE is -0.19%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EMBCV is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PROC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while OPTN trades at $9.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EMBCV's ROE is -0.19%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, EMBCV is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check OPTN's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ZOM trades at $0.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EMBCV's ROE is -0.19%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, EMBCV is more volatile compared to ZOM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ZOM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while GRVI trades at $4.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EMBCV's ROE is -0.19%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EMBCV is more volatile compared to GRVI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check GRVI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZYBT has a market cap of 73.5M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ZYBT trades at $1.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is -7.05. In terms of profitability, EMBCV's ROE is -0.19%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, EMBCV is more volatile compared to ZYBT. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ZYBT's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TLPH has a market cap of 72.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TLPH trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -4.52. In terms of profitability, EMBCV's ROE is -0.19%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EMBCV is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check TLPH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ZYNE trades at $1.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EMBCV's ROE is -0.19%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EMBCV is more volatile compared to ZYNE. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ZYNE's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SSIC trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EMBCV's ROE is -0.19%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EMBCV is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SSIC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while VLNS trades at $0.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EMBCV's ROE is -0.19%, compared to VLNS's ROE of N/A. Regarding short-term risk, EMBCV is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check VLNS's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while DRRX trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EMBCV's ROE is -0.19%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, EMBCV is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check DRRX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, INCR has a market cap of 57.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while INCR trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -2.23. In terms of profitability, EMBCV's ROE is -0.19%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EMBCV is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check INCR's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while JUPW trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EMBCV's ROE is -0.19%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EMBCV is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check JUPW's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CPHI has a market cap of 44.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CPHI trades at $1.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CPHI's P/E ratio is -1.72. In terms of profitability, EMBCV's ROE is -0.19%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EMBCV is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check CPHI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while QLI trades at $5.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, EMBCV's ROE is -0.19%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EMBCV is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check QLI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while HEXO trades at $0.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EMBCV's ROE is -0.19%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EMBCV is more volatile compared to HEXO. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check HEXO's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RMTI has a market cap of 30.8M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while RMTI trades at $7.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -7.42. In terms of profitability, EMBCV's ROE is -0.19%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EMBCV is more volatile compared to RMTI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check RMTI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AYTU trades at $2.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -1.23. In terms of profitability, EMBCV's ROE is -0.19%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EMBCV is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AYTU's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, TXMD has a market cap of 24.1M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while TXMD trades at $2.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is 105.96. In terms of profitability, EMBCV's ROE is -0.19%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, EMBCV is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check TXMD's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CYTH trades at $0.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EMBCV's ROE is -0.19%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EMBCV is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CYTH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while EVOK trades at $11.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EMBCV's ROE is -0.19%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, EMBCV is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check EVOK's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, OPTH has a market cap of 15.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while OPTH trades at $4.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas OPTH's P/E ratio is -17.38. In terms of profitability, EMBCV's ROE is -0.19%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, EMBCV is more volatile compared to OPTH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check OPTH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ACRX trades at $0.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EMBCV's ROE is -0.19%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EMBCV is more volatile compared to ACRX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ACRX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, BFRIW has a market cap of 13.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, EMBCV's ROE is -0.19%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, EMBCV is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check BFRIW's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, COSM has a market cap of 11.7M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while COSM trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.29. In terms of profitability, EMBCV's ROE is -0.19%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EMBCV is more volatile compared to COSM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check COSM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while AGRX trades at $1.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EMBCV's ROE is -0.19%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EMBCV is more volatile compared to AGRX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check AGRX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while NLTX trades at $3.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EMBCV's ROE is -0.19%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, EMBCV is more volatile compared to NLTX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check NLTX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while LCI trades at $0.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas LCI's P/E ratio is -0.04. In terms of profitability, EMBCV's ROE is -0.19%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EMBCV is more volatile compared to LCI. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check LCI's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ADMP trades at $0.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EMBCV's ROE is -0.19%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EMBCV is more volatile compared to ADMP. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ADMP's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, YCBD has a market cap of 6.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while YCBD trades at $0.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is -1.49. In terms of profitability, EMBCV's ROE is -0.19%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EMBCV is more volatile compared to YCBD. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check YCBD's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, GELS has a market cap of 5.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while GELS trades at $0.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -1.14. In terms of profitability, EMBCV's ROE is -0.19%, compared to GELS's ROE of -0.25%. Regarding short-term risk, EMBCV is more volatile compared to GELS. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check GELS's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while MNK trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas MNK's P/E ratio is -0.44. In terms of profitability, EMBCV's ROE is -0.19%, compared to MNK's ROE of -0.36%. Regarding short-term risk, EMBCV is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check MNK's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while FLGC trades at $7.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EMBCV's ROE is -0.19%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, EMBCV is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check FLGC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, UPC has a market cap of 3.8M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while UPC trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas UPC's P/E ratio is -0.75. In terms of profitability, EMBCV's ROE is -0.19%, compared to UPC's ROE of -0.03%. Regarding short-term risk, EMBCV is more volatile compared to UPC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check UPC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SBFM trades at $1.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SBFM's P/E ratio is -0.20. In terms of profitability, EMBCV's ROE is -0.19%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, EMBCV is more volatile compared to SBFM. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SBFM's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PLXP trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EMBCV's ROE is -0.19%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EMBCV is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check PLXP's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SHPH has a market cap of 2.5M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SHPH trades at $4.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SHPH's P/E ratio is -0.20. In terms of profitability, EMBCV's ROE is -0.19%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, EMBCV is more volatile compared to SHPH. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SHPH's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while ATNX trades at $0.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EMBCV's ROE is -0.19%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EMBCV is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check ATNX's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SNOA has a market cap of 2.3M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SNOA trades at $1.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SNOA's P/E ratio is -1.16. In terms of profitability, EMBCV's ROE is -0.19%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, EMBCV is more volatile compared to SNOA. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SNOA's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while PROCW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas PROCW's P/E ratio is N/A. In terms of profitability, EMBCV's ROE is -0.19%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EMBCV is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check PROCW's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while RDHL trades at $0.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas RDHL's P/E ratio is 0.12. In terms of profitability, EMBCV's ROE is -0.19%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, EMBCV is more volatile compared to RDHL. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check RDHL's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, SXTC has a market cap of 1.8M. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while SXTC trades at $3.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas SXTC's P/E ratio is 1.18. In terms of profitability, EMBCV's ROE is -0.19%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, EMBCV is more volatile compared to SXTC. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check SXTC's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while YCBD-PA trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, EMBCV's ROE is -0.19%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, EMBCV is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for EMBCV.Check YCBD-PA's competition here

Embecta Corp. (NASDAQ: EMBCV) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EMBCV stands at 1.9B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, EMBCV is priced at $33.33 on the NASDAQ, while CYTHW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EMBCV currently has a P/E ratio of N/A, whereas CYTHW's P/E ratio is N/A. In terms of profitability, EMBCV's ROE is -0.19%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, EMBCV is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for EMBCV.Check CYTHW's competition here